Neil DeSena is a distinguished finance professional and one of the founding Managing Partners of SenaHill Partners, LP, a pioneering merchant bank dedicated to the financial technology sector. In addition to this role, Neil serves as a Board Member at Symbiont.io, contributing to the integration of blockchain technology within traditional finance. As an Advisory Board Member for Excision BioTherapeutics Inc., Neil supports the advancement of gene editing therapeutics. Neil also presides over DeSena Investments, a family office specializing in Angel round investing, and has held positions as an Independent Board Member at Pico Quantitative Trading and Managing Director at Goldman Sachs, where leadership of the REDI Product Development initiative was undertaken. Earlier, Neil was a Partner and Managing Director at Spear, Leeds & Kellogg, leading the REDI Products Division.
Sign up to view 0 direct reports
Get started